Targeting Doctors to Lower Drug Costs By Dan

New Post Public Reply Private Reply Replies (1) Message Board
incubus
Targeting Doctors to Lower Drug Costs

By Dan Gilmore

Mar. 9, 2016

Medication, like every other aspect of America’s health care industry, is a metastasizing mass of government rules, large companies and some feeble attempts at the free market. Recently, the Centers for Medicare and Medicaid Services introduced a rule1 that tries to reduce the number of times doctors prescribe medication with high cost. Currently, the cost of medication through Medicare Plan B runs the government about $19 billion a year. Currently, when doctors prescribe medication, they receive a payout of 6% of the cost of the drug. Drug costs $100? Doctor gets paid $6. Some point out that this “commission,” if you will, encourages doctors to scribble out prescriptions for more expensive drugs.

Dr. Allen Litcher, CEO of the American Society of Clinical Oncology told the WSJ that the government is laying the blame for high drug costs on the wrong people. “It is inappropriate for CMS to manipulate choice of treatment for cancer patients using heavy-handed reimbursement techniques,” he said. “Physicians did not create the problem of drug pricing and its solution should not be on their backs.”

The new rule is more complicated — not an encouraging first sign for reform — and it would first drop the premium to 2.5% of the price of the drug and go to a fee-based system. The goal is to remove the incentive from doctors to prescribe more expensive drugs for better cash and instead put the focus on what drugs work, preferably less expensive drugs.

But the larger problem remains: Just how did the nation’s medication get so expensive? Last year, WSJ examined the factors2, comparing the cost of name-brand drugs across several countries against the cost the U.S. government pays for them. Most of the time, American patients pay more than someone in, say, Norway or England. Some of the costs passed on to the consumer are because drug companies can advertise to consumers in the United States, unlike a more socialist nation where they are banned from doing so. In other instances, drug entrepreneurs like Martin Shkreli realize they can make a killing by jacking up prices. When he was called before Congress3 in February, he smirked, almost laughed at the lawmakers during the hearings and all the while remained silent before their questioning. Later Shkreli tweeted, “Hard to accept that these imbeciles represent the people in our government.”

But perhaps the biggest factor for the price disparity is that Norway, England and other “enlightened” socialist countries place price controls on drugs. This means that if drug companies want money to spend on research and development, they have to pull it from the pockets of consumers. It’s something America could do too, but at the cost of more regulation and less ability to develop life-saving drugs. Yet there the market forces remain. Patients can still insist on more inexpensive medication.

( What this article fails to include is that generics have different fillers, inactive ingredients that can have side effects and fail to provide the same potency. Many of these drugs are now produced overseas. Some generics have been found to have nonrelated active drugs in them. Our government doesn't do an effective job of screening them, tells us to take them. This deters new drug development due to underfunding especially for the smaller drug companies. A lot of articles on Google talking about it. Know this from personal experience. Even the pharmacy tries to force people to generics. My doctor told me to take brand only. And we have two Democrat 'candidates' attacking the industry causing it to plummet. The insurance companies now feel justified to force people to use them or pay much higher price for their medications.)

http://patriotpost.us/posts/41202

1.http://www.wsj.com/articles/u-s-officials-propose-test-program-aimed-at-lowering-medicare-drug-costs-1457470874
2.http://www.wsj.com/articles/why-the-u-s-pays-more-than-other-countries-for-drugs-1448939481
3.http://www.usatoday.com/story/money/2016/02/04/martin-shkreli-congressional-testimony-turing-pharmaceuticals-valeant-fda-drug-prices/79808004/

www.newsmax.com/Health/Health-News/generic-drugs-danger-recall/2014/09/23/id/596332/

http://www.huffingtonpost.com/2015/02/22/gene...30194.html

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MetroScape: Local Roots Fuel Bold DFW Growth Plans

Updated Category News Views 40

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...

Continue Reading
Fidelis Care Opens $120K Workforce Grants for Aid

Updated Category News Views 40

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Continue Reading
Milwaukee Art Museum Secures $10 Million Preservation Fund

Updated Category News Views 0

In a world where art meets aspiration, the Quadracci family’s latest $10 million gift to the Milwaukee Art Museum speaks volumes. With a vision to guarantee the future of architectural elegance, they’re making sure Santiago Calatrava’s stunning Quadracci Pavilion remains a cornerstone on Milwaukee’s skyline. For twenty-five years, this striking creation has not...

Continue Reading
J.H. Strain & Sons' Asset Sale Seals a New Era

Updated Category News Views 0

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Continue Reading
Greentown Labs Builds Momentum in Climate Innovation

Updated Category News Views 55

Paving the Way for Climate-Tech Pioneers Ah, Massachusetts—where the perfect storm of bright minds and groundbreaking innovation is brewing. It's not all just Harvard and MIT. It's programs like Greentown Labs' First Valley Fellowship stirring the pot, ushering in a new era of climate and energy startups. We're talking a robust second year for the Fellowship, where...

Continue Reading
Housing Transition: Unlocking the Trillion-Dollar Pathway

Updated Category News Views 44

A Trillion-Dollar Balancing Act at COP31 The housing market: one giant balancing act, now with a trillion bucks at stake. The Sustainable Real Estate Forum (SREF) didn't hold back in their new white paper, "The Trillion-Dollar Housing Transition." They've outlined the monumental shift needed to get our housing not just affordable, but sustainable too. The Lay of the Land...

Continue Reading
Quad Sees Marginal Gains Amid Industry Challenges

Updated Category News Views 0

Treading Water with a Splash of Strategic Moves When you're in the thick of market shifts, sometimes it's not about big leaps but staying afloat with purpose. That's what Quad's recent financial release seems to hint at. A steady net sales figure hovering at $587 million for Q3 2026, barely a nudge compared to last year's numbers, sets the tone. It's not the fireworks...

Continue Reading
Corgi Insurance Eyes $100B Auto Market with New Launch

Updated Category News Views 154

Leaping Into a Booming Market Well, it looks like someone lit a fire under Corgi Insurance, and they're ready to chase bigger bones. They’ve just rolled out a product called Corgi Business Auto, signaling quite a bold move into the hefty, nearly $100 billion U.S. commercial auto insurance arena. Now, as an old hand at this game, my ears perk up whenever I see a player...

Continue Reading
Mission Wealth's Rising Stars Shine Bright in 2026

Updated Category News Views 19

The financial world can be a ruthless arena, especially when you're under 40 and trying to make your mark. But in 2026, two up-and-comers from Mission Wealth are doing just that—earning spots on the coveted InvestmentNews Rising Stars list. Spotlight on Kulha and Dragan Andrew Kulha, with his legal and financial acumen, breaks down estate strategies like a seasoned...

Continue Reading
UPM Defies Market Challenges: Strong Q3 Cash Flow

Updated Category News Views 102

UPM's Impressive Q3 Performance Amidst Challenges UPM-Kymmene Corporation just dropped their Q3 numbers, and let me tell ya, there's a lot to digest. In the face of some pretty gnarly market conditions—think destocking and those pesky cost inflations—they've managed to pull a rabbit out of the hat with strong cash flow. That's not a small feat, folks; it's a damn...

Continue Reading
ticles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles